EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study

Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo und 23 weitere

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.1015 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Shou-Wu Lee und 34 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Hepatitis C. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kaohsiung Medical University, Ministry of Health and Welfare, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains largely uncertain. We aimed to explore the impact of DAA therapy on overall survival (OS) in HCC patients using a nationwide cohort study.

Methods

We utilized the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) database to include all adults receiving a DAA therapy for HCV, excluding those with other viral infections, liver transplantation, non-HCC malignancies, and terminal-staged HCC. We respectively analyzed the adjusted odds ratio (aOR) for sustained virological response (SVR) and adjusted hazard ratio (aHR) for OS.

Results

Between December 2013 and December 2020, 2,205 (9.3%) patients with HCC and 21,569 (90.7%) patients without HCC were include. The SVR rates were 96.6% in the HCC group and 98.8% in the non-HCC group (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntiviral AgentsHepatitis CHepatitis C, ChronicHumansMaleFemaleMiddle AgedAgedTaiwanCohort StudiesHepacivirusSustained Virologic ResponseAdultProportional Hazards ModelsOdds RatioRegistriesRisk Factors

Stichwörter der Autor:innen

AntiviralsChronic hepatitis CLiver cancerSurvivalSustained virological response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung, Taiwan.
  • Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
  • Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

Förderung

  • Kaohsiung Medical University
  • Ministry of Health and Welfare
  • National Science and Technology Council
  • Taichung Veterans General Hospital
  • Kaohsiung Medical University Hospital

Zitieren

APA

Lee, S. W., Yang, S. S., Tsai, P. C., Huang, C. F., Chen, C. Y., Hung, C. H., Chen, C. H., Tai, C. M., Cheng, P. N., Kuo, H. T., Tseng, K. C., Mo, L. R., Lo, C. C., Huang, Y. H., Lin, H. C., Lee, P. L., Bair, M. J., Chang, T. S., Lin, C. Y., …, & TACR investigators (2025). Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.1015

Vancouver

Lee SW, Yang SS, Tsai PC, Huang CF, Chen CY, Hung CH, et al. Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.1015

BibTeX
@article{Lee2025,
  author = {Lee, Shou-Wu and Yang, Sheng-Shun and Tsai, Pei-Chien and Huang, Chung-Feng and Chen, Chi-Yi and Hung, Chao-Hung and Chen, Chien-Hung and Tai, Chi-Ming and Cheng, Pin-Nan and Kuo, Hsing-Tao and Tseng, Kuo-Chih and Mo, Lein-Ray and Lo, Ching-Chu and Huang, Yi-Hsiang and Lin, Han-Chieh and Lee, Pei-Lun and Bair, Ming-Jong and Chang, Te-Sheng and Lin, Chun-Yen and Wang, Szu-Jen and Hsieh, Tsai-Yuan and Yang, Tzeng-Hue and Peng, Cheng-Yuan and Yang, Chi-Chieh and Chong, Lee-Won and Huang, Chien-Wei and Lin, Chih-Wen and Chu, Cheng-Hsin and Tsai, Ming-Chang and Kao, Jia-Horng and Liu, Chun-Jen and Chuang, Wan-Long and Lee, Teng-Yu and Yu, Ming-Lung and TACR investigators, TACR investigators},
  title = {Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.1015}
}
Kostenlos starten →